Clinical Trial Detail

NCT ID NCT03935347
Title Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.